HomeCompareCMGHY vs ABBV

CMGHY vs ABBV: Dividend Comparison 2026

CMGHY yields 2262.44% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMGHY wins by $31484616573.94M in total portfolio value
10 years
CMGHY
CMGHY
● Live price
2262.44%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31484616574.04M
Annual income
$28,966,071,943,936,024.00
Full CMGHY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CMGHY vs ABBV

📍 CMGHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMGHYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMGHY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMGHY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMGHY
Annual income on $10K today (after 15% tax)
$192,307.69/yr
After 10yr DRIP, annual income (after tax)
$24,621,161,152,345,620.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CMGHY beats the other by $24,621,161,152,324,564.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMGHY + ABBV for your $10,000?

CMGHY: 50%ABBV: 50%
100% ABBV50/50100% CMGHY
Portfolio after 10yr
$15742308287.07M
Annual income
$14,483,035,971,980,398.00/yr
Blended yield
92.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CMGHY
No analyst data
Altman Z
-35.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMGHY buys
0
ABBV buys
0
No recent congressional trades found for CMGHY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMGHYABBV
Forward yield2262.44%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$31484616574.04M$102.3K
Annual income after 10y$28,966,071,943,936,024.00$24,771.77
Total dividends collected$31307465919.12M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CMGHY vs ABBV ($10,000, DRIP)

YearCMGHY PortfolioCMGHY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$236,944$226,244.34$11,550$430.00+$225.4KCMGHY
2$5,263,560$5,010,029.68$13,472$627.96+$5.25MCMGHY
3$109,645,522$104,013,512.85$15,906$926.08+$109.63MCMGHY
4$2,142,284,668$2,024,963,958.80$19,071$1,382.55+$2142.27MCMGHY
5$39,268,233,638$36,975,989,043.35$23,302$2,095.81+$39268.21MCMGHY
6$675,449,314,887$633,432,304,895.13$29,150$3,237.93+$675449.29MCMGHY
7$10,905,545,213,930$10,182,814,447,000.18$37,536$5,121.41+$10905545.18MCMGHY
8$165,321,093,267,716$153,652,159,888,811.12$50,079$8,338.38+$165321093.22MCMGHY
9$2,353,780,028,132,576$2,176,886,458,336,119.20$69,753$14,065.80+$2353780028.06MCMGHY
10$31,484,616,574,037,880$28,966,071,943,936,024.00$102,337$24,771.77+$31484616573.94MCMGHY

CMGHY vs ABBV: Complete Analysis 2026

CMGHYStock

Chaoda Modern Agriculture (Holdings) Limited, an investment holding company, engages in growing and selling agricultural products in Hong Kong and internationally. The company offers fruits and vegetables, including white cauliflower, cherry tomato, cabbage, mini cucumber, purple cabbage, netted melon, tangerine, broccoli, lettuce, gourd, sweet pepper, sweet corn, choi sum, chinese cabbage, and pumpkin. It also breeds and sells livestock. In addition, the company is involved in the provision of agency services; distribution and trading of crops; wholesale and logistics of vegetables and fruits; property holding activities; wholesale of potato's products; and research and development of organism technologies. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Full CMGHY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CMGHY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMGHY vs SCHDCMGHY vs JEPICMGHY vs OCMGHY vs KOCMGHY vs MAINCMGHY vs JNJCMGHY vs MRKCMGHY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.